Viking Therapeutics (1VT) Price & Analysis

76 Followers

1VT Stock Chart & Stats

€28.40

€0.05(0.16%)

At close: Jul 27 4:00 PM EDT

€28.40

€0.05(0.16%)

Day’s Range― - ―

52-Week Range€20.97 - €40.00

Previous CloseN/A

Volume52.00

Average Volume (3M)307.00

Market Cap

€2.98B

Enterprise Value€4.04K

Total Cash (Recent Filing)€501.66M

Total Debt (Recent Filing)€4.09M

Price to Earnings (P/E)―

Beta0.59

Next Earnings

Oct 28, 2026

EPS Estimate

-0.93

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.66

Shares Outstanding116,652,940

10 Day Avg. Volume272

30 Day Avg. Volume307

Financial Highlights & Ratios

PEG Ratio-0.05

Price to Book (P/B)6.20

Price to Sales (P/S)0.00

P/FCF Ratio-14.22

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€78.43

Price Target Upside176.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering14

EPS Forecast (FY)-3.97

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Late-stage Clinical ExecutionFully enrolled, large Phase III trials represent meaningful execution progress and reduce enrollment-related uncertainty for VK2735. The programs provide a clear path toward pivotal efficacy data, while the 78-week endpoint is designed to assess durable weight-loss outcomes.

Promising VK2735 EfficacyMeaningful weight reduction across both injectable and oral formulations supports the commercial relevance of VK2735 and broadens potential patient access. Positive early efficacy, including substantial oral response rates, strengthens the pipeline while Phase III testing advances.

Liquidity And Low LeverageMinimal debt limits fixed financial obligations and preserves flexibility while Viking funds pivotal trials. Management’s runway estimate into 2028 gives the company time to generate important clinical milestones before needing additional capital, supporting development continuity.

Bears Say

Pre-revenue And Widening LossesThe absence of meaningful product revenue leaves Viking dependent on financing or future transactions to support operations. Rapidly widening losses show that the expanding development platform has not yet produced commercial earnings, keeping profitability dependent on successful approvals.

Accelerating Cash BurnEscalating operating and free-cash-flow deficits indicate that late-stage trials are materially increasing the company’s funding requirement. Persistent cash consumption can eventually require equity issuance or other financing, creating dilution risk even though current liquidity remains substantial.

Clinical And Maintenance UncertaintyMaintenance tolerability and durability remain important unresolved questions for the obesity franchise, while VK3019 is still at an early stage. Short follow-up and limited human validation make future efficacy, safety, and differentiation outcomes uncertain over the development cycle.

Viking Therapeutics News

Unusually active option classes on open September 10th

Unusual total active option classes on open include: Clean Energy (CLNE), iShares DJ US Real Estate Index Fund...

9d ago

FCX

Der Aktionaer editor speculates on timing of Viking Therapeutics data

Michel Doepke, editor at Der Aktionaer, posted on X: “$VKTX In the past, the company has often released...

26d ago

VKTX

Viking Therapeutics price target lowered to $65 from $75 at JPMorgan

JPMorgan analyst Hardik Parikh lowered the firm’s price target on Viking Therapeutics (VKTX) to $65 from $75 and...

1M ago

VKTX

3 Best Stocks With 100%+ Upside to Buy This Week, According to Analysts

Analysts see strong momentum in some stocks this week, including Viking Therapeutics ($VKTX), USA Rare Earth ($USAR), and NextNav...

1M ago

USAR

Viking Therapeutics participates in a conference call with Cantor

Conference call with management to be held on August 13 at 11 am hosted by Cantor. Published first...

1M ago

VKTX

Oppenheimer says VK2735’s options create compelling reason to own Viking

Oppenheimer says that while investors focus on the imminent clinical readout for Viking Therapeutics (VKTX)’ VK2735 to demonstrate...

2M ago

VKTX

Viking Therapeutics: Why This Clinical-Stage, Licensed-Technology Play Is a Highly Speculative Bet for Equity Investors

Viking Therapeutics (VKTX) has disclosed a new risk, in the Accounting & Financial Operations category. Viking Therapeutics is...

2M ago

VKTX

Viking Therapeutics Earnings Call Signals Obesity Push

Viking Therapeutics (($VKTX)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

VKTX

Viking Therapeutics price target raised to $114 from $107 at Canaccord

Canaccord raised the firm’s price target on Viking Therapeutics (VKTX) to $114 from $107 and keeps a Buy...

2M ago

VKTX

Viking Therapeutics files automatic mixed securities shelf

06:13 EDT Viking Therapeutics (VKTX) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

VKTX

Viking Therapeutics Buy Rating Reaffirmed as Obesity Franchise Advances; $102 Price Target Maintained

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics and keeping the price target...

2M ago

VKTX

Analyst Reaffirms Buy on Viking Therapeutics, Citing Best‑in‑Class Obesity Portfolio and Upcoming Clinical Readouts

William Blair analyst Andy Hsieh has reiterated their bullish stance on VKTX stock, giving a Buy rating on...

2M ago

VKTX

Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year

At June 30, Viking held cash, cash equivalents and short-term investments of $502M vs. $706M as of December...

2M ago

VKTX

Viking Therapeutics options imply 8.1% move in share price post-earnings

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 3:1. Implied volatility suggests the...

2M ago

VKTX

1VT FAQ

What was Viking Therapeutics’s price range in the past 12 months?

Viking Therapeutics lowest stock price was €20.97 and its highest was €40.00 in the past 12 months.

What is Viking Therapeutics’s market cap?

Viking Therapeutics’s market cap is €2.98B.

When is Viking Therapeutics’s upcoming earnings report date?

Viking Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 39 days.

How were Viking Therapeutics’s earnings last quarter?

Viking Therapeutics released its earnings results on Jul 29, 2026. The company reported -€0.958 earnings per share for the quarter, beating the consensus estimate of -€1.073 by €0.116.

Is Viking Therapeutics overvalued?

According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viking Therapeutics pay dividends?

Viking Therapeutics does not currently pay dividends.

What is Viking Therapeutics’s EPS estimate?

Viking Therapeutics’s EPS estimate is -0.93.

How many shares outstanding does Viking Therapeutics have?

Viking Therapeutics has 116,652,940 shares outstanding.

What happened to Viking Therapeutics’s price movement after its last earnings report?

Viking Therapeutics reported an EPS of -€0.958 in its last earnings report, beating expectations of -€1.073. Following the earnings report the stock price went down -4.94%.

Which hedge fund is a major shareholder of Viking Therapeutics?

Currently, no hedge funds are holding shares in DE:1VT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viking Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-36.96%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Viking Therapeutics

Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.

Viking Therapeutics (1VT) Earnings & Revenues

Historic Earnings Reports

1VT Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call highlights substantial clinical progress: fully enrolled large Phase III programs for subcutaneous VK2735, positive Phase II efficacy for both subcutaneous and oral formulations (notably up to 14.7% and 12.2% mean weight loss, respectively), initiation of an early-stage amylin/calcitonin program (VK3019), and organizational hires to support commercialization. These scientific and pipeline milestones are balanced against materially higher R&D spend, widening net losses and a meaningful cash decline (~28.9% year-to-date). Management reiterated cash runway into 2028 and expects cash burn to taper, while noting upcoming maintenance study data and oral Phase III initiation later in the year. Overall, clinical momentum and promising efficacy data are dominant positives, while financial burn and early-stage uncertainties are notable negatives.View all DE:1VT earnings summaries

1VT Stock 12 Month Forecast

Average Price Target

€78.43

▲(176.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"€21","100":"€100","40.75":"€40.8","60.5":"€60.5","80.25":"€80.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":99.24884346,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€99.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":78.42690042416666,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€78.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56.58925285,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€56.59</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,40.75,60.5,80.25,100],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,33.849911035384615,39.29982207076923,44.74973310615385,50.199644141538464,55.64955517692308,61.099466212307696,66.54937724769232,71.99928828307694,77.44919931846155,82.89911035384617,88.34902138923078,93.7989324246154,{"y":99.24884346,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,32.24822310955128,36.09644621910256,39.944669328653845,43.79289243820513,47.64111554775641,51.48933865730769,55.33756176685897,59.18578487641025,63.03400798596154,66.88223109551282,70.73045420506409,74.57867731461539,{"y":78.42690042416666,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.4,30.568404065384613,32.736808130769234,34.90521219615385,37.07361626153846,39.242020326923075,41.41042439230769,43.57882845769231,45.747232523076924,47.91563658846154,50.08404065384616,52.25244471923077,54.42084878461539,{"y":56.58925285,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.495,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.6,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.555,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.2,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.79,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.05,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.9,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.4,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >